Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Rhea-AI Summary

Marker Therapeutics (MRKR), a clinical-stage immuno-oncology company, announced its participation in the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators & Investors Symposium. Juan Vera, M.D., President and CEO, will present on December 12, 2024, at 1:30 PM EST.

The presentation will showcase Marker's technology and clinical developments in T cell-based immunotherapies for treating hematological malignancies and solid tumor indications. Registered participants can access the presentation through the event portal, and a replay will be available on the Company's IR website under Events & Presentations.

HOUSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the Ladenburg Thalmann & Co. Virtual Oncology Innovators & Investors Symposium. This virtual investor event will be held on December 12, 2024.

Dr. Vera will present an overview of Marker’s technology and clinical developments on Thursday, December 12, 2024, at 1:30 PM EST.

Details of the presentation are as follows:

Event:	2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators & Investors Symposium
Date:	December 12, 2024, at 1:30 PM EST
Location:	Virtual Event

Registered participants will have access to the presentation through the event portal on the day of the event. After the event,  Dr. Vera’s presentation will be available for replay on the Company’s IR website under Events & Presentations.

About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a Houston, TX-based clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. Clinical trials that enrolled more than 200 patients across various hematological and solid tumor indications showed that the Company’s autologous and allogeneic multiTAA-specific T cell products were well tolerated and demonstrated durable clinical responses. Marker’s goal is to introduce novel T cell therapies to the market and improve patient outcomes. To achieve these objectives, the Company prioritizes the preservation of financial resources and focuses on operational excellence. Marker’s unique T cell platform is strengthened by non-dilutive funding from U.S. state and federal agencies supporting cancer research.

To receive future press releases via email, please visit:
https://www.markertherapeutics.com/email-alerts.

Forward-Looking Statements
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases;  the timing, conduct and success of our clinical trials of our product candidates, including MT-601 for the treatment of patients with lymphoma. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at WWW.SEC.GOV. The Company assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release except as may be required by law.

Contacts
Investors
TIBEREND STRATEGIC ADVISORS, INC.
Jonathan Nugent
205-566-3026
jnugent@tiberend.com

FAQ

When is Marker Therapeutics (MRKR) presenting at the Ladenburg Thalmann Virtual Oncology Symposium?

Marker Therapeutics (MRKR) will present on December 12, 2024, at 1:30 PM EST at the Ladenburg Thalmann Virtual Oncology Symposium.

What will be discussed in Marker Therapeutics' (MRKR) presentation at the 2024 Ladenburg symposium?

The presentation will provide an overview of Marker's technology and clinical developments in T cell-based immunotherapies for hematological malignancies and solid tumor treatments.

How can investors access Marker Therapeutics' (MRKR) Ladenburg symposium presentation?

Registered participants can access the presentation through the event portal on December 12, 2024, and a replay will be available afterward on the Company's IR website under Events & Presentations.